Antibody and Cell-Mediated Immune Responses Are Correlates of Protection Against Influenza Infection in Vaccinated Older Adults

Overview

Journal Vaccines (Basel)

Date 2021 Jan 12

PMID 33430191

Citations 7

Authors

Chris P Verschoor

Melissa K Andrew

Mark Loeb

Graham Pawelec

Laura Haynes

George A Kuchel

Janet E McElhaney

Affiliations

Soon will be listed here.

Abstract

Despite efforts to design better vaccines for older adults, the risk for serious complications of influenza remains disproportionately high. Identifying correlates of vaccine effectiveness and understanding the heterogeneity of health outcomes in older adults are key to the vaccine development pipeline. We sought correlates of protection against laboratory-confirmed influenza illness (LCII) in a 4-year randomized trial of standard versus high-dose influenza vaccination of adults 65 years and older. To this end, we quantified serum hemagglutination-inhibition (HAI) titers and interferon-gamma (IFNγ) and interleukin-10 (IL-10) secretion by virus-challenged peripheral blood mononuclear cells. Of the 608 participants included, 26 developed either A/H3N2-( = 17) or B-LCII ( = 9) at 10-20 weeks post-vaccination. Antibody titres for A/H3N2 at 4-weeks post-vaccination were significantly associated with protection against LCII, where every 1-standard deviation increase reduced the odds of A/H3N2-LCII by 53%. Although B-titres did not correlate with protection against B-LCII, the fold-increase in IFNγ:IL-10 ratios from pre- to 4-weeks post-vaccination was significantly associated with protection against B-LCII, where every 1-standard deviation increase reduced the odds by 71%. Our results suggest that both antibody and cell-mediated immune measures are valuable and potentially complementary correlates of protection against LCII in vaccinated older adults, although this may depend on the viral type causing infection.

Citing Articles

Measuring Vaccine Responses in the Multiplex Era.

Ayling K, Vedhara K, Fairclough L Methods Mol Biol. 2024; 2868:149-162.

PMID: 39546230 DOI: 10.1007/978-1-0716-4200-9_9.

Factors Influencing the Intention of Chinese Adults to Recommend COVID-19 Vaccination for Specific or Non-Specific Groups.

Pang Y, Li B, Li T, Yang T, Deng J, Deng W Healthcare (Basel). 2024; 12(14).

PMID: 39057520 PMC: 11276595. DOI: 10.3390/healthcare12141377.

Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial.

Schmader K, Liu C, Flannery B, Rountree W, Auerbach H, Barnett E Immun Ageing. 2023; 20(1):30.

PMID: 37393237 PMC: 10314373. DOI: 10.1186/s12979-023-00355-7.

The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial.

Martin D, Cadar A, Panier H, Torrance B, Kuchel G, Bartley J Immun Ageing. 2023; 20(1):18.

PMID: 37131271 PMC: 10152024. DOI: 10.1186/s12979-023-00343-x.

The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.

Janssens Y, Joye J, Waerlop G, Clement F, Leroux-Roels G, Leroux-Roels I Front Immunol. 2022; 13:959379.

PMID: 36052083 PMC: 9424642. DOI: 10.3389/fimmu.2022.959379.

References

DiazGranados C, Dunning A, Kimmel M, Kirby D, Treanor J, Collins A . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014; 371(7):635-45. DOI: 10.1056/NEJMoa1315727. View

McElhaney J, Verschoor C, Andrew M, Haynes L, Kuchel G, Pawelec G . The immune response to influenza in older humans: beyond immune senescence. Immun Ageing. 2020; 17:10. PMC: 7204009. DOI: 10.1186/s12979-020-00181-1. View

Hoover M, Rotermann M, Sanmartin C, Bernier J . Validation of an index to estimate the prevalence of frailty among community-dwelling seniors. Health Rep. 2013; 24(9):10-7. View

McElhaney J, Gentleman B . Cell-Mediated Immune Response to Influenza Using Ex Vivo Stimulation and Assays of Cytokine and Granzyme B Responses. Methods Mol Biol. 2015; 1343:121-41. DOI: 10.1007/978-1-4939-2963-4_11. View

He W, Tan G, Mullarkey C, Lee A, Lam M, Krammer F . Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A. 2016; 113(42):11931-11936. PMC: 5081650. DOI: 10.1073/pnas.1609316113. View

Mitnitski A, Mogilner A, Rockwood K . Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2003; 1:323-36. PMC: 6084020. DOI: 10.1100/tsw.2001.58. View

Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W . Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013; 19(10):1305-12. DOI: 10.1038/nm.3350. View

Dunning A, DiazGranados C, Voloshen T, Hu B, Landolfi V, Talbot H . Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial. Clin Vaccine Immunol. 2016; 23(3):228-35. PMC: 4783426. DOI: 10.1128/CVI.00604-15. View

Kissling E, Pozo F, Buda S, Vilcu A, Rizzo C, Gherasim A . Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18). Vaccine X. 2019; 3:100042. PMC: 6807025. DOI: 10.1016/j.jvacx.2019.100042. View

10.

Zimmerman R, Nowalk M, Chung J, Jackson M, Jackson L, Petrie J . 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis. 2016; 63(12):1564-1573. PMC: 5146719. DOI: 10.1093/cid/ciw635. View

11.

Searle S, Mitnitski A, Gahbauer E, Gill T, Rockwood K . A standard procedure for creating a frailty index. BMC Geriatr. 2008; 8:24. PMC: 2573877. DOI: 10.1186/1471-2318-8-24. View

12.

Andrew M, Shinde V, Ye L, Hatchette T, Haguinet F, Dos Santos G . The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. J Infect Dis. 2017; 216(4):405-414. PMC: 5853583. DOI: 10.1093/infdis/jix282. View

13.

Thompson W, Shay D, Weintraub E, Brammer L, Cox N, Anderson L . Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289(2):179-86. DOI: 10.1001/jama.289.2.179. View

14.

Ferdinands J, Gaglani M, Martin E, Middleton D, Monto A, Murthy K . Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2018; 220(8):1265-1275. PMC: 6743848. DOI: 10.1093/infdis/jiy723. View

15.

Merani S, Kuchel G, Kleppinger A, McElhaney J . Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol. 2017; 107:116-125. PMC: 5871551. DOI: 10.1016/j.exger.2017.09.015. View

16.

Haq K, Fulop T, Tedder G, Gentleman B, Garneau H, Meneilly G . Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status. J Gerontol A Biol Sci Med Sci. 2016; 72(9):1163-1170. PMC: 5861868. DOI: 10.1093/gerona/glw216. View

17.

Shahid Z, Kleppinger A, Gentleman B, Falsey A, McElhaney J . Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine. 2010; 28(38):6145-51. PMC: 2948951. DOI: 10.1016/j.vaccine.2010.07.036. View

18.

Li J, Zhou Y, Kou Y, Yu X, Zheng Z, Yang X . Interim estimates of divergence date and vaccine strain match of human influenza A(H3N2) virus from systematic influenza surveillance (2010-2015) in Hangzhou, southeast of China. Int J Infect Dis. 2015; 40:17-24. DOI: 10.1016/j.ijid.2015.09.013. View

19.

Lancaster G, Febbraio M . The immunomodulating role of exercise in metabolic disease. Trends Immunol. 2014; 35(6):262-9. DOI: 10.1016/j.it.2014.02.008. View

20.

Loeb N, Andrew M, Loeb M, Kuchel G, Haynes L, McElhaney J . Frailty Is Associated With Increased Hemagglutination-Inhibition Titers in a 4-Year Randomized Trial Comparing Standard- and High-Dose Influenza Vaccination. Open Forum Infect Dis. 2020; 7(5):ofaa148. PMC: 7255647. DOI: 10.1093/ofid/ofaa148. View